CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity

Immunology Letters

Volumn 148, Issue 1, 2012, Pages 83-89

  Chen, Xin ^a   Du, Yong ^a   Huang, Zhiming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

CD4+CD25+ regulatory T cell; Dendritic cell; Hepatocellular carcinoma; Suppressor mechanism

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPHOCYTE FUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; CELL COMMUNICATION; CELL LINE, TUMOR; CELLS, CULTURED; CTLA-4 ANTIGEN; DENDRITIC CELLS; DOWN-REGULATION; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; IMMUNITY; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-12; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOCYTE COUNT; MALE; MICE; MICE, INBRED BALB C; SPLEEN; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866694932     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.09.002     Document Type: Article

References (21)

1. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
2. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25) Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
3. Mizukami Y., Kono K., Kawaguchi Y., Akaike H., Kamimura K., Suqai H., et al. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 2008, 98:148-153.
4. Nummer D., Suri-payer E., Schmitz-Winnenthal H., Bonertz A., Galindo L., Antolovich D., et al. Role of tumor endothelium in CD4+CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst 2007, 99:1188-1199.
5. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-2761.
6. Ormandy L.A., Hillemann T., Wedemeyer H., Manns M.P., Greten T.F., Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005, 65:2457-2464.
7. Yu P., Lee Y., Liu W., Krausz T., Chong A., Schreiber H., et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005, 201:779-791.
8. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendrite cells. Annu Rev Immunol 2000, 18:767-811.
9. Ballestrero A., Boy D., Moran E., Cirmena G., Brossart P., Nencioni A. Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev 2008, 60:173-183.
10. Palmer D.H., Midgley R.S., Mirza N., Torr E.E., Ahmed F., Steele J.C., et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009, 49:124-132.
11. Butterfield L.H., Ribas A., Dissette V.B., Lee Y., Yang J.Q., De la Rocha P., et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006, 12:2817-2825.
12. Nicolas L., Marilyn M., Yi Z., Jessica C., Angela R., Marjan S., et al. Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10. Cancer Immunol Immunother 2007, 4:8-59.
13. Marshall N.A., Chrisite L.E., Munro L.R., Culligan D.J., Johnston P.W., Barker R.N., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103:1755-1762.
14. Cabrera R., Ararat M., Erika A.E., Cao M., Xu Y., Wasserfall C., et al. Influence of serum and soluble CD25(sCD25) on regulatory and effector T cell function in Hepatocellular Carcinoma. Scand J Immunol 2010, 72:293-301.
15. Wang G., Khattar M., Guo Z., Miyahara Y., Linkes S.P., Sun Z., et al. IL-2-deprivation and TGF-beta are two non-redundant suppressor mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+CD25- cell activation. Immunol Lett 2010, 132:61-68.
16. Read S., Malmstron V., Cytotoxic Powrie F. T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000, 192:295-302.
17. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006, 6:295-307.
18. Almand B., Clark J.I., Nikitina E., Van Beynen J., English N.R., Knight S.C., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001, 166:678-689.
19. Chaux P., Favre N., Martin M., Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 1997, 72:619-624.
20. Verginis P., Li H.S., Carayanniotis G. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+T Cells. J Immunol 2005, 174:7433-7439.
21. LaRosa D.F., Gelman A.E., Rahman A.H., Zhang J., Turka L.A., Walsh P.T. CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells. Immunol Lett 2007, 108:183-188.